Misplaced Pages

5-Methoxytryptamine

Clinical data
Other names	5-MeO-T; 5-OMe-T; 5-MeOT; 5-MeO-TPA; 5-MT; MT; 5-Hydroxytryptamine methyl ether; Serotonin methyl ether; O-Methylserotonin; O-Methyl-5-HT; Mexamine; Meksamin; Mekasamin; PAL-234
Routes of administration	Orally inactive
Drug class	Non-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
Pharmacokinetic data
Metabolism	MAO-ATooltip Monoamine oxidase A
Identifiers
IUPAC name 2-(5-Methoxy-1H-indol-3-yl)ethanamine
CAS Number	608-07-1
PubChem CID	1833
IUPHAR/BPS	107
ChemSpider	1767
UNII	3VMW6141KC
KEGG	C05659
ChEBI	CHEBI:2089
ChEMBL	ChEMBL8165
CompTox Dashboard (EPA)	DTXSID60209638
ECHA InfoCard	100.009.231
Chemical and physical data
Formula	C11H14N2O
Molar mass	190.246 g·mol
3D model (JSmol)	Interactive image
SMILES O(c1cc2c(cc1)cc2CCN)C
InChI InChI=1S/C11H14N2O/c1-14-9-2-3-11-10(6-9)8(4-5-12)7-13-11/h2-3,6-7,13H,4-5,12H2,1H3 Key:JTEJPPKMYBDEMY-UHFFFAOYSA-N
(verify)

5-Methoxytryptamine (5-MT, 5-MeO-T, or 5-OMe-T), also known as serotonin methyl ether or O-methylserotonin and as mexamine, is a tryptamine derivative closely related to the neurotransmitters serotonin and melatonin. It has been shown to occur naturally in the body in low levels, especially in the pineal gland. It is formed via O-methylation of serotonin or N-deacetylation of melatonin.

5-MT is a highly potent and non-selective serotonin receptor agonist and shows serotonergic psychedelic-like effects in animals. However, it is inactive in humans, at least orally, likely due to rapid metabolism by monoamine oxidase (MAO). The levels and effects of 5-MT are dramatically potentiated by monoamine oxidase inhibitors (MAOIs) in animals.

Biosynthesis

5-MT can be formed by O-methylation of serotonin mediated by hydroxyindole O-methyltransferase (HIOMT) or by N-deacetylation of melatonin. It is also a precursor of 5-MeO-DMT in some species.

Pharmacology

Pharmacodynamics

5-MT acts as an agonist of the serotonin 5-HT₁, 5-HT₂, 5-HT₄, 5-HT₆, and 5-HT₇ receptors.

It is an extremely potent serotonin 5-HT_2A receptor agonist in vitro, with an EC₅₀Tooltip half-maximal effective concentration of 0.503 nM. This was more potent than any other tryptamine evaluated in two large series of compounds. For comparison, 5-MeO-DMT had an EC₅₀ of 3.87 nM (7.7-fold lower) and dimethyltryptamine (DMT) had an EC₅₀ of 38.3 nM (76-fold lower).

5-MT has been said to be 25- and 400-fold selective for the serotonin 5-HT_2B receptor over the serotonin 5-HT_2A and 5-HT_2C receptors, respectively.

5-MT, in contrast to the closely related melatonin, has no affinity for the melatonin receptors. However, it may be converted into melatonin in the body, and hence may indirectly act as a melatonin receptor agonist.

5-MT shows dramatically reduced activity as a monoamine releasing agent compared to tryptamine and serotonin.

Effects in animals and humans

5-MT dose-dependently induces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and this effect is reversed by serotonin 5-HT_2A receptor antagonists. As such, it may be a hallucinogen in humans. 5-MT is only briefly mentioned in several places in Alexander Shulgin's TiHKAL and its psychoactive effects are not described. Besides psychedelic-like effects, 5-MT produces a "hyperactivity syndrome" in rodents. It produces various other effects in animals as well.

Pharmacokinetics

Distribution

5-MT is able to cross the blood–brain barrier and enter the central nervous system with peripheral administration in animals.

Metabolism

5-MT is metabolized by deamination by monoamine oxidase (MAO), specifically monoamine oxidase A (MAO-A) and to a much lesser extent by monoamine oxidase B (MAO-B).

Brain levels of 5-MT following central administration of 5-MT in rats were potentiated by 20-fold by the MAO-A inhibitor clorgyline and by 5.5-fold by the MAO-B inhibitor selegiline. Similarly, levels of serotonin and phenethylamine were also greatly elevated by these drugs. In accordance with the potentiation of brain levels of 5-MT by MAOIs, the behavioral effects of centrally administered 5-MT in rats, for instance in the conditioned avoidance response test, are markedly enhanced by MAOIs, including by the dual MAO-A and MAO-B inhibitor iproniazid and by clorgyline and selegiline.

Similarly to rat findings, pineal gland levels of endogenous 5-MT are dramatically elevated by the MAO-A inhibitor clorgyline and by the dual MAO-A and MAO-B inhibitor pargyline in hamsters, and plasma levels of exogenous 5-MT are greatly elevated by these MAOIs as well. Conversely, selegiline was ineffective in elevating brain or plasma 5-MT levels in hamsters.

The non-selective MAO-A and MAO-B inhibitor tranylcypromine has been frequently used to potentiate the effects of 5-MT in animal studies.

5-MT is orally inactive in humans presumably due to rapid metabolism by MAO-A.

Metabolites of 5-MT include 5-methoxyindole-3-acetic acid (5-MIAA) and 5-methoxytryptophol. It may also be metabolized into melatonin.

Chemistry

5-MT, also known as 5-methoxytryptamine or as 5-hydroxytrypamine O-methyl ether, is a substituted tryptamine and a derivative of serotonin (5-hydroxytryptamine) and precursor of melatonin (N-acetyl-5-methoxytryptamine).

It is closely related to other 5-methoxylated tryptamines such as 5-MeO-NMT, 5-MeO-DMT, 5-MeO-DPT, 5-MeO-DiPT, 5-MeO-MiPT, 5-MeO-DALT, and 5-MeO-AMT. 5-MeO-AMT is orally active in humans, in contrast to 5-MT, and could be thought of as a sort of orally active form of 5-MT. Some other notable analogues of 5-MT include tryptamine, 2-methyl-5-hydroxytryptamine, 5-benzyloxytryptamine, 5-carboxamidotryptamine, 5-methyltryptamine, 5-(nonyloxy)tryptamine, α-methyl-5-hydroxytryptamine, acetryptine (5-acetyltryptamine), and isamide (N-chloroacetyl-5-methoxytryptamine), among others.

The predicted log P of 5-MT is 0.5 to 1.41.

References

1. ^ Nichols DE (2012). "Structure–activity relationships of serotonin 5‐HT 2A agonists". Wiley Interdisciplinary Reviews: Membrane Transport and Signaling. 1 (5): 559–579. doi:10.1002/wmts.42. ISSN 2190-460X.
2. ^ Nichols DE (2018). "Chemistry and Structure-Activity Relationships of Psychedelics". Curr Top Behav Neurosci. 36: 1–43. doi:10.1007/7854_2017_475. PMID 28401524.
3. ^ Pévet P (1983). "Is 5-methoxytryptamine a pineal hormone?". Psychoneuroendocrinology. 8 (1): 61–73. doi:10.1016/0306-4530(83)90041-0. PMID 6136058.
4. ^ Galzin AM, Eon MT, Esnaud H, Lee CR, Pévet P, Langer SZ (1988). "Day-night rhythm of 5-methoxytryptamine biosynthesis in the pineal gland of the golden hamster (Mesocricetus auratus)". J. Endocrinol. 118 (3): 389–397. doi:10.1677/joe.0.1180389. PMID 2460575.
5. ^ Tan DX, Hardeland R, Back K, Manchester LC, Alatorre-Jimenez MA, Reiter RJ (August 2016). "On the significance of an alternate pathway of melatonin synthesis via 5-methoxytryptamine: comparisons across species". J Pineal Res. 61 (1): 27–40. doi:10.1111/jpi.12336. PMID 27112772.
6. ^ "PDSP Database". UNC (in Zulu). Retrieved 3 December 2024.
7. ^ Liu T. "BindingDB BDBM82087 2-(5-methoxy-1H-indol-3-yl)ethanamine::5-MT::5-Methoxytryptamine hydrochloride::CAS_66-83-1::tryptamine, 5-Methoxy". BindingDB. Retrieved 3 December 2024.
8. ^ Blough BE, Landavazo A, Partilla JS, Decker AM, Page KM, Baumann MH, Rothman RB (October 2014). "Alpha-ethyltryptamines as dual dopamine-serotonin releasers". Bioorg Med Chem Lett. 24 (19): 4754–4758. doi:10.1016/j.bmcl.2014.07.062. PMC 4211607. PMID 25193229.
9. ^ Blough BE, Landavazo A, Decker AM, Partilla JS, Baumann MH, Rothman RB (October 2014). "Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes". Psychopharmacology (Berl). 231 (21): 4135–4144. doi:10.1007/s00213-014-3557-7. PMC 4194234. PMID 24800892.
10. ^ Przegaliński E, Zebrowska-Lupina I, Wójcik A, Kleinrok Z (1977). "5-Methoxytryptamine-induced head twitches in rats". Pol J Pharmacol Pharm. 29 (3): 253–261. PMID 267911.
11. ^ Green AR, Hughes JP, Tordoff AF (August 1975). "The concentration of 5-methoxytryptamine in rat brain and its effects on behaviour following its peripheral injection". Neuropharmacology. 14 (8): 601–606. doi:10.1016/0028-3908(75)90127-6. PMID 126386.
12. ^ Prozialek WC, Vogel WH (February 1978). "Deamination of 5-methoxytryptamine, serotonin and phenylethylamine by rat MAO in vitro and in vivo". Life Sci. 22 (7): 561–569. doi:10.1016/0024-3205(78)90334-x. PMID 272480.
13. ^ Prozialeck WC, Vogel WH (February 1979). "MAO inhibition and the effects of centrally administered LSD, serotonin, and 5-methoxytryptamine on the conditioned avoidance response in rats". Psychopharmacology (Berl). 60 (3): 309–310. doi:10.1007/BF00426673. PMID 108709. In contrast, MAO inhibition greatly increased brain levels of 5-HT and 5-MT (Prozialeck and Vogel, 1978). For instance, clorgyline and deprenyl increased brain levels of 5-HT 8.5-fold and 4.4-fold and of 5-MT 20-fold and 5-fold, respectively.
14. ^ Raynaud F, Pévet P (February 1991). "5-Methoxytryptamine is metabolized by monoamine oxidase A in the pineal gland and plasma of golden hamsters". Neurosci Lett. 123 (2): 172–174. doi:10.1016/0304-3940(91)90923-h. PMID 2027530.
15. ^ Vetulani J, Byrska B, Reichenberg K (1979). "Head twitches produced by serotonergic drugs and opiates after lesion of the mesostriatal serotonergic system of the rat". Pol J Pharmacol Pharm. 31 (4): 413–423. PMID 316525.
16. ^ Kolasa K, Kleinrok Z, Rajtar G, Juszkiewicz M (1984). "Effects of histamine and H1 and H2-receptor antagonists on wet-dog-shake episodes in rats induced with tranylcypromine and 5-methoxytryptamine". Acta Physiol Pol. 35 (3): 225–230. PMID 6152672.
17. Volk B, Nagy BJ, Vas S, Kostyalik D, Simig G, Bagdy G (2010). "Medicinal chemistry of 5-HT5A receptor ligands: a receptor subtype with unique therapeutical potential". Curr Top Med Chem. 10 (5): 554–578. doi:10.2174/156802610791111588. PMID 20166946.
18. Wu PH, Gurevich N, Carlen PL (1988). "Serotonin-1A receptor activation in hippocampal CA1 neurons by 8-hydroxy-2-(di-n-propylamino)tetralin, 5-methoxytryptamine and 5-hydroxytryptamine". Neurosci. Lett. 86 (1): 72–76. doi:10.1016/0304-3940(88)90185-1. PMID 2966313. S2CID 21620262.
19. Yamada J, Sugimoto Y, Yoshikawa T, Horisaka K (1997). "Hyperglycemia induced by the 5-HT receptor agonist, 5-methoxytryptamine, in rats: involvement of the peripheral 5-HT2A receptor". Eur J Pharmacol. 323 (2–3): 235–240. doi:10.1016/S0014-2999(97)00029-0. PMID 9128844.
20. Amemiya N, Hatta S, Takemura H, Ohshika H (1996). "Characterization of the contractile response induced by 5-methoxytryptamine in rat stomach fundus strips". Eur J Pharmacol. 318 (2–3): 403–409. doi:10.1016/S0014-2999(96)00777-7. PMID 9016931.
21. Craig DA, Eglen RM, Walsh LK, Perkins LA, Whiting RL, Clarke DE (1990). "5-Methoxytryptamine and 2-methyl-5-hydroxytryptamine-induced desensitization as a discriminative tool for the 5-HT3 and putative 5-HT4 receptors in guinea pig ileum". Naunyn-Schmiedeberg's Arch Pharmacol. 342 (1): 9–16. doi:10.1007/bf00178965. PMID 2402303. S2CID 24743785.
22. Boess FG, Monsma Jr FJ, Carolo C, Meyer V, Rudler A, Zwingelstein C, Sleight AJ (1997). "Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells". Neuropharmacology. 36 (4–5): 713–720. doi:10.1016/S0028-3908(97)00019-1. PMID 9225298. S2CID 41813873.
23. Hemedah M, Coupar IM, Mitchelson FJ (1999). "[3H]-Mesulergine labels 5-HT7 sites in rat brain and guinea-pig ileum but not rat jejunum". Br J Pharmacol. 126 (1): 179–188. doi:10.1038/sj.bjp.0702293. PMC 1565797. PMID 10051134.
24. Glennon RA, Dukat M, Westkaemper RB (2000-01-01). "Serotonin Receptor Subtypes and Ligands". American College of Neurophyscopharmacology. Archived from the original on 21 April 2008. Retrieved 2008-04-11.
25. Encyclopedia of Signaling Molecules. Cham: Springer International Publishing. 2018. doi:10.1007/978-3-319-67199-4. ISBN 978-3-319-67198-7. 1-Structure and properties of 5-HT2B receptors: 1.1-Selective agonists: - 5-Methoxytryptamine is also 25- and 400-fold selective over the 5-HT2A and 5-HT2C receptor sites, respectively.
26. Zlotos DP (2012). "Recent progress in the development of agonists and antagonists for melatonin receptors". Curr Med Chem. 19 (21): 3532–3549. doi:10.2174/092986712801323153. PMID 22680635.
27. Zlotos DP (2014). "Development of Agonists and Antagonists for Melatonin Receptors". Melatonin and Melatonergic Drugs in Clinical Practice. New Delhi: Springer India. p. 97–116. doi:10.1007/978-81-322-0825-9_7. ISBN 978-81-322-0824-2.
28. Nakamura M, Fukushima H (April 1978). "Effects of reserpine, para-chlorophenylalanine, 5,6-dihydroxytryptamine and fludiazepam on the head twitches induced by 5-hydroxytryptamine or 5-methoxytryptamine in mice". J Pharm Pharmacol. 30 (4): 254–256. doi:10.1111/j.2042-7158.1978.tb13219.x. PMID 24719.
29. ^ Przegaliński E, Baran L, Palider W, Bigajska K (1978). "On the central antiserotonin activity of benzoctamine and opipramol". Pol J Pharmacol Pharm. 30 (6): 781–790. PMID 582625.
30. Baran L, Maj J, Rogóz Z, Skuza G (1979). "On the central antiserotonin action of trazodone". Pol J Pharmacol Pharm. 31 (1): 25–33. PMID 482164.
31. ^ Przegaliński E, Baran L, Palider W, Siwanowicz J (April 1979). "The central action of pizotifen". Psychopharmacology (Berl). 62 (3): 295–300. doi:10.1007/BF00431961. PMID 111296.
32. De Montigny C, Aghajanian GK (1977). "Preferential action of 5-methoxytryptamine and 5-methoxydimethyltryptamine on presynaptic serotonin receptors: A comparative iontophoretic study with LSD and serotonin". Neuropharmacology. 16 (12): 811–818. doi:10.1016/0028-3908(77)90142-3.
33. Shulgin A (1997). TiHKAL: The Continuation (PDF). Transform Press. ISBN 978-0-9630096-9-2. Retrieved 2 November 2024. One of its most broadly studied properties is that of protecting an experimental animal against the damage of being exposed to radiation. It was unexpectedly observed that our essential and favorite neurotransmitter serotonin was every bit as effective as a radioprotective agent. In efforts to make this natural compound more accessible to the damaged animal, it was studied as the unacetylated Omethyl ether. This simple compound, 5-methoxytryptamine (5-MeO-T, or Mexamine) has been mentioned under the recipe for 5-MeO-DMT in its possible effects in potentiating CNS-active drugs. But here it deserves to be highlighted for its protection against radiation. Two structural modification directions of 5-methoxytryptamine have been thoroughly explored. A A 5-MeO-T anti-radiation, not a psychedelic ? Removal of both methyl groups from the nitrogen gives 5- methoxytryptamine (5-MeO-T) which has been explored most extensively by Soviet researchers as a treatment for exposure to radiation; this aspect of its action is discussed and expanded upon in the commentary under Melatonin. It is also known by the trade name Mexamine and has been looked at as a potentiator of centrally active drugs.
34. "5-MeO-T - PiHKAL·info". Isomer Design. 11 November 2024. Retrieved 3 December 2024.
35. Boullin DJ, Green AR (1976). "5-Methoxytryptamine: stimulation of 5-HT receptors mediating the rat hyperactivity syndrome and blood platelet aggregation". Adv Biochem Psychopharmacol. 15: 127–140. PMID 15408.
36. Galzin AM, Langer SZ (July 1986). "Potentiation by deprenyl of the autoreceptor-mediated inhibition of -5-hydroxytryptamine release by 5-methoxytryptamine". Naunyn Schmiedebergs Arch Pharmacol. 333 (3): 330–333. doi:10.1007/BF00512949. PMID 3093900.
37. ^ "5-Methoxytryptamine". PubChem. Retrieved 3 December 2024.
38. "Metabolite 5-Methoxytryptamine". DrugBank Online. Retrieved 3 December 2024.
39. "5-Methoxytryptamine". ChemSpider. 10 June 2024. Retrieved 3 December 2024.

External links

• 5-Methoxytryptamine - isomer design

• 5-HT1A agonists
• 5-HT2A agonists
• Human drug metabolites
• Mexamines
• Psychedelic tryptamines
• Serotonin receptor agonists